Neuromodulation Devices
•26 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (26)
| Company | Market Cap | Price |
|---|---|---|
|
BSX
Boston Scientific Corporation
Neuromodulation devices including Intracept intraosseous nerve ablation system.
|
$141.48B |
$97.56
+2.18%
|
|
SYK
Stryker Corporation
OptaBlate BVN system is a neuromodulation/pain-management device.
|
$133.34B |
$365.60
+4.82%
|
|
MDT
Medtronic plc
Neuromodulation Devices cover the spine and brain stimulation technologies (e.g., Inceptiv, Percept) highlighted in the pipeline.
|
$124.88B |
$100.49
+3.21%
|
|
GMED
Globus Medical, Inc.
Neuromodulation devices via Nevro spinal cord stimulation platform and expansion.
|
$12.22B |
$92.84
+2.62%
|
|
LIVN
LivaNova PLC
Directly manufactures/distributes Neuromodulation Devices, including VNS Therapy and proximal hypoglossal nerve stimulation systems.
|
$3.45B |
$63.67
+0.70%
|
|
ATEC
Alphatec Holdings, Inc.
SafeOp neural monitoring systems used during spine surgery.
|
$3.14B |
$21.54
+1.60%
|
|
INSP
Inspire Medical Systems, Inc.
Inspire V is a neuromodulation device designed to treat obstructive sleep apnea, representing Inspire's core product category.
|
$2.80B |
$96.26
+1.58%
|
|
ITGR
Integer Holdings Corporation
Neuromodulation devices are a high-growth served market for Integer and align with its product portfolio.
|
$2.79B |
$80.74
+1.28%
|
|
PCRX
Pacira BioSciences, Inc.
IOvera's mechanism relates to neuromodulation/nerve-targeted therapy, aligning with Neuromodulation Devices.
|
$1.13B |
$25.05
-0.18%
|
|
BVS
Bioventus Inc.
Peripheral Nerve Stimulation products (TalisMann, StimTrial) are neuromodulation devices.
|
$625.88M |
$7.51
-0.79%
|
|
AVNS
Avanos Medical, Inc.
The RFA portfolio (ESENTEC, TRIDENT, COOLIEF) places Avanos in the neuromodulation devices category.
|
$524.81M |
$11.62
+2.74%
|
|
NPCE
NeuroPace, Inc.
Core product Neuromodulation device (RNS System) delivering brain-responsive, on-demand therapy for drug-resistant epilepsy.
|
$524.67M |
$16.31
+2.84%
|
|
BWAY
BrainsWay Ltd.
Core product: BrainsWay's Deep TMS neuromodulation devices.
|
$351.87M |
$21.25
+0.35%
|
|
OBIO
Orchestra BioMed Holdings, Inc.
AVIM therapy uses neuromodulation to affect autonomic nervous system responses, fitting Neuromodulation Devices.
|
$228.77M |
$4.41
+4.01%
|
|
CVRX
CVRx, Inc.
CVRx's Barostim is a neuromodulation device (implantable) that modulates the autonomic nervous system via baroreflex activation for heart failure.
|
$200.58M |
$7.83
+2.02%
|
|
NYXH
Nyxoah S.A.
Genio is a neuromodulation implant system (implantable medical device) for obstructive sleep apnea.
|
$161.63M |
$4.80
+2.23%
|
|
STIM
Neuronetics, Inc.
NeuroStar Advanced Therapy System is a non-invasive neuromodulation device; the direct product of the company.
|
$93.24M |
$1.68
+18.79%
|
|
VANI
Vivani Medical, Inc.
Vivani's Neurostimulation division (Cortigent) assets exist and are being spun off, representing Neuromodulation Devices.
|
$74.65M |
$1.25
-0.79%
|
|
NRXS
NeurAxis, Inc.
Core product line: Neuromodulation devices (IB-Stim PENFS).
|
$43.48M |
$4.49
+1.81%
|
|
NMTC
NeuroOne Medical Technologies Corporation
Core product category: neuromodulation devices used to treat epilepsy and pain via brain stimulation and ablation.
|
$42.44M |
$0.96
+13.03%
|
|
ECOR
electroCore, Inc.
Directly markets and sells neuromodulation medical devices (gammaCore, Quell, Truvaga, Sparrow Ascent, TAC-STIM).
|
$35.87M |
$4.86
+2.75%
|
|
COCH
Envoy Medical, Inc.
Cochlear implants operate by neuromodulating auditory pathways, classifying them as neuromodulation devices.
|
$15.22M |
$0.70
-1.17%
|
|
NXL
Nexalin Technology, Inc.
Core product is non-invasive neuromodulation devices for brain stimulation (Gen-2 SYNC, Gen-3 HALO).
|
$11.15M |
$0.74
+15.31%
|
|
HSDT
Solana Company
PoNS is a non-invasive neuromodulation device produced by the company for gait and balance rehabilitation.
|
$3.61M |
$3.31
-1.19%
|
|
ZYXI
Zynex, Inc.
NexWave and TensWave are neuromodulation/electrotherapy devices, placing the company in the neuromodulation devices category.
|
$3.33M |
$0.13
+2.22%
|
|
AMIX
Autonomix Medical, Inc. Common Stock
Core platform is a catheter-based Neuromodulation Device designed to sense and ablate peripheral nerves.
|
$3.10M |
$0.63
+4.38%
|
Loading company comparison...
Loading industry trends...
Loading research report...
